Day 1 - 18th of November 2022


Time Title Speaker & Moderator
12.00-13.00 Arrival and lunch
Session 1: Biomarkers in migraine
13.00-13.05 Welcome Fredrik Blomstrand
13.05-13.25 Treatment response as a biomarker Mikko Kallela
13.25-13.45 Biomarkers with focus on genetics Andrea Carmine Belin
13.45-14.00 Discussion Mikko Kallela
14.00-14.20 Break
Session 2: Migraine in pediatric & elderly patients
14.20-14.40 Epidemiology Christofer Lundqvist
14.40-15.00 Migraine in elderly Messoud Ashina
15.00-15.20 Migraine in pediatric Tine Poole
15.20-15.40 Discussion Tine Poole
15.40-16.00 Break
Session 3: The educated migraine patient
16.00-16.20 Misconceptions on migraine and treatments - social media, Google, etc. Thien Do
16.20-16.40 Patient FAQs & demands and how to address M. Hassinen and Aud Dueland
16.40-17.00 Discussion Mattias Linde
18.30 Dinner

Day 2 - 19th of November 2022


Time Title Speaker & Moderator
Session 4: Difficult to treat patients
09.00-09.20 New EHF guideline on the use of MAb’s for migraine prevention Simona Sacco
09.20-09.40 Comorbidities and management Gurdal Sahin
09.40-10.00 Combining preventative therapies Mattias Linde
10.00-10.20 Multidisciplinary management Maren Eriksen
10.20-10.40 Discussion Lars Bendtsen
10.40-11.10 Break
Session 5: a-CGRP registries and RWE
11.10-11.30 Safety, tolerability and possible interactions of the MAbs Ville Artto
11.30-11.50 Rationale for switching of preventative treatments Lars Bendtsen
11.50-12.10 The outlook of a tertiary treatment and research center Erling Tronvik
12.10-12.30 Discussion and closure Mattias Linde
12.30 Lunch

All timings are CET

The agenda is subject to change

To Teva Denmark's knowledge the meeting is in compliance with the rules of ENLI and will be reported to ENLI prior to the meeting.